Why D-Wave Quantum Stock Keeps Going Up

The U.S. Department of Commerce confirmed it will award D-Wave Quantum $100 million under the CHIPS and Science Act to help improve qubit counts and error rates. The grant is positive for liquidity, but D-Wave burned more than $100 million over the last 12 months, so the funding only adds about a year of runway. Shares have already surged 66% in three trading days, reflecting a sharp sentiment-driven move rather than a change in near-term profitability.

Analysis

The market is treating this as a credibility event, not just a funding event. For QBTS, the real second-order effect is that a federal stamp of approval can compress its cost of capital and improve customer conversion, but the grant size is still too small to change the company’s medium-term dependency on external financing. If the stock keeps running on momentum, the better trade may be on volatility normalization rather than upside continuation, because the move has already priced in a multi-quarter improvement in survivability.

IBM looks like the stealth winner because it is the only name here with both balance sheet durability and industrial relevance to capture follow-on contracting, integration work, and ecosystem positioning. GFS benefits less from quantum economics directly, but the policy framing reinforces domestic advanced manufacturing as a priority, which can support valuation multiples in any onshore capex cycle. The more important chain reaction is that smaller adjacent quantum suppliers and integration partners may see a funding window open even if they are not named, creating a temporary halo across the theme.

The contrarian read is that this may be the peak narrative event for QBTS rather than the start of a durable rerating. Government money often accelerates technical milestones but does not eliminate commercialization risk, and the market tends to overestimate how quickly public support translates into revenue. If the next catalyst is not a real customer contract or measurable error-rate improvement, the stock can give back a large fraction of the move once speculators fade.

Near term, the setup is most attractive as a relative-value and volatility trade rather than an outright directional long. The cleanest expression is to own the names with durable balance sheets and short the weakest balance-sheet beta in the theme if the tape extends on retail flow. Longer term, the grant is more useful as an option on survival than a thesis on profitability.

Key Decisions for Investors

• Short QBTS into strength over the next 1-3 weeks if price remains extended after the policy headline; use tight risk controls because the name can overshoot on retail flow, but expect mean reversion if no follow-on technical milestone is announced.
• Long IBM vs short QBTS as a relative-value pair for the next 1-3 months; IBM has the balance sheet and contracting leverage to convert policy support into durable economics, while QBTS remains dependent on repeated capital raises.
• Add GFS on pullbacks over the next 2-6 weeks as a lower-beta policy beneficiary; the upside is multiple support from domestic manufacturing priority, with less execution risk than the pure-play quantum names.
• Buy QBTS puts or put spreads 1-2 months out if implied volatility remains elevated; this is a favorable way to express disappointment risk because the stock’s recent move likely left it priced for a best-case funding narrative.
• Use any further strength in quantum-related names to trim exposure and rotate into higher-quality AI/infrastructure beneficiaries; the risk/reward shifts quickly once the market realizes grants extend runway, but do not solve commercialization.